MedIntelliBase® NewsTips  
May 2006

Your monthly newsletter from the
"better way to access market intelligence" people at

A Better stay up-to-date Home


Late-Breaking Updates:

  • Just released - Late breaking trial and emerging technology updates from the mid-May EuroPCR06 conference.
  • Coverage of the Endovascular Congress, the ACC.06 and SIR 2006 conferences in our Interventional Medicine Series is now completed.
  • All updates expand your access to our extensive archives of pivotal trials and registries as well as emerging and established technologies.

These MedIntelliBase™ MarketTracks titles are newly updated:

  • Cardiovascular (CV) Therapeutics
  • Endovascular (EV) Therapeutics
  • Carotid (Carotid) Therapeutics & Stroke Prevention.

Table of Contents

Late Breaking News -- Cardiovascular Therapeutics MarketTrack

Link of the Month

MIB MarketTracks SMArt Volumes

Fun Fact of the Month

MedIntelliBase Introduction>> A Better Way.

More Information Available at


Cardiovascular Therapeutics MarketTrack - Heparin-Sirolimus DES

The Synchronnium heparin-sirolimus stent system from Sahajanand Medical Technologies of India was discussed by Dr. Suhas Lele at the EuroPCR06 meeting on Thursday, May 18. Please see our coverage of this new dual-drug DES within our CV Therapeutics MIB MarketTrack below:

Synchronnium heparin-sirolimus DES

Return to Top

Link of the Month

MIB MarketTracks SMArt Volumes - Mechanisms of Inflammation Before & After Percutaneous Interventions

Two primary episodes of inflammation can be associated with percutaneous cardiovascular and endovascular interventions - an initial "inflammatory activation" resulting from atherosclerosis and a "secondary inflammatory activation" following an intervention:

Mechanisms of Inflammation

Restenosis does not occur without vascular injury associated with a percutaneous intervention - the very procedure that is intended to eliminate the original stenosis often causes restenosis. It is this relationship that drives the industry to produce technologies such as bare metal stents (BMS), drug-eluting stents (DES) and now heparin-DES to minimize the need for follow-up procedures.

MIB MarketTracks chronicle the development of these technologies and hundreds more designed to fight restenosis and improve the outcomes of vascular interventions. Click here to request a Real-Time, Online MIB tour and a Free 15-Day Subscription.

Return to Top

Fun Fact of the Month

MedIntelliBase Introduction >> A Better Way.

--On Line, On-Time and On-Topic, On Demand, Up-to-Date-->

Does this "quest for Market Intelligence" sound familiar?

  1. Search for multi-client market studies
  2. Agonize over the high prices
  3. “Bite the bullet” and purchase a report
  4. Skim the report for useful information
  5. Marvel at the lack of depth and double- or triple- spaced pages
  6. Recognize that the information in the report was only slightly out of date when the report was published - 18 months ago
  7. Get frustrated at the inability to find what you need
  8. Write your report or your business plan that you know should be better, more in depth...if only you had better information
  9. Vow that next time, you’ll find a better way!

MedIntelliBase MarketTracks..."A Better Way"

  • Access your MarketTracks from anywhere – online service
  • Packed with the latest information - updated as new industry and late breaking trials announcements occur at all the major conferences***
  • Receive significantly more information than competing reports - twice the depth & breadth of coverage
  • Easy to search - all information in a cross-linked, searchable database
  • Fits within your budget - competitively priced and customized subscriptions to meet your needs!
  • Access offline as well - PDF report & database search results downloadable & printable - all included in your acquisition price!
  • PLUS coming soon! - More detailed market stats & projections - U.S., EU & global - down to market share by product category
You get much greater value from our customizable MIB MarketTracks than from standard market reports. You choose the exact depth and breadth of intelligence required, enabling your team to realize the greatest value for your market intelligence money.

***Late breaking as well as archived information on pivotal trials and registries and emerging technologies remains available to you within our databases for years to come - enabling you to track years of developments and history so you and your team do not repeat past mistakes.

Click here to request more information, a Real-Time MIB tour AND a Free 15-Day Subscription!

Return to Top

More Information Available at!

You can find more in-depth information about the details noted above and many other technologies and clinical studies we have been tracking over the years in our MedIntelliBase MarketTracks >> visit our website at

We will be pleased to help you access the critical intelligence you need to make informed product development and business investment decisions.

Contact us for more information...


  1. MedIntelliBase NewsTips is free and you are welcome to continue receiving it as long as you wish. If at any time you wish to cancel just click the Safe Unsubscribe link below.
  2. We will not share your name and e-mail address with anyone.
  3. Feel free to share or reproduce the information in this MedIntelliBase NewsTips e-newsletter (in whole or part) as long as proper mention and copyright notice is given to MedIntelliBase and The Next Phase Publishing, Inc.
  4. If you are not the original recipient of this newsletter and would like to receive future issues, just click the Forward link below or drop me a line.

© The Next Phase® Consultancy, Inc. 2006. All rights reserved.

Editor: Vicky Hunsicker Sanko
The Next Phase Publishing, Inc.
Mobile - 206/669-3053
Phone - 425/869-8724
Toll Free - 800/390-2756
Fax - 425/869-9397

Market Research Analyst: Jordan Zornes
The Next Phase Publishing, Inc.
Phone - 425/894-4147
Fax - 425/869-9397

Return to Top